Early enzyme replacement therapy prevents dental and craniofacial abnormalities in a mouse model of mucopolysaccharidosis type VI

Early enzyme replacement therapy prevents dental and craniofacial abnormalities in a mouse model of mucopolysaccharidosis type VI

Mucopolysaccharidosis VI (MPS VI) is a hereditary lysosomal storage disease caused by the absence of the enzyme arylsulfatase B (ARSB). Craniofacial defects are common in MPS VI patients and manifest as abnormalities of the facial bones, teeth, and temporomandibular joints. Although enzyme replaceme...

Full description

Bibliographic Details
Main Authors: Rohit Nagpal, Gina Georgi, Sarah Knauth, Carmen Schmid-Herrmann, Nicole Muschol, Thomas Braulke, Bärbel Kahl-Nieke, Michael Amling, Thorsten Schinke, Till Koehne, Julian Petersen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Physiology
Subjects:
MPS VI
Arsbm/m mice
condyle
alveolar bone loss
craniofacial malformations
Online Access:https://www.frontiersin.org/articles/10.3389/fphys.2022.998039/full

Internet

https://www.frontiersin.org/articles/10.3389/fphys.2022.998039/full

Similar Items